80 results about "Policosanol" patented technology

A composition is provided containing at least 90% of policosanols obtained from rice bran wax, wherein the policosanols contain from about 25 to about 35% of octacosanol, and its use in providing significant improvements in total cholesterol and/or LDL reduction in subjects in need thereof.

Methods, systems and formulations for normalizing and improving human body chemistry and the body's natural ability to heal itself. In one embodiment a system including effective amounts of a digestive enzyme, soluble and insoluble fiber, laxative, probiotics, vitamin C, potassium, protease enzymes, lipase, lysine, taurine, proline, choline, inositol, inositol hexaphosphate, policosanol, charcoal, bentonite clay, thyme, ascorbic acid, magnesium citrate, calcium citrate, methylsulfonyl methane, cayenne pepper, magnesium, potassium, ester-c, ginger and niacin, lysine calcium, stevia leaf, citric acid, a tincture of bayberry bark, juniper berries, yam root, cramp bark, golden seal root, fennel seed, uva ursi leaves, ginger root, lobelia herb, catnip herb, and peppermint leaf, golden seal root, Echinacea angustifolia root, ginger root, and licorice root, a tincture of black walnut hulls, venus fly trap, chaparral, wormwood, licorice root, slippery elm, cloves and comfrey root, burdock root, sheep sorrel, rhubarb root, slippery elm, olive leaf and yarrow flower is provided.

A composition is provided which contains policosanol and HMG-Co-A reductase inhibitor and which may be used for treating and or reducing hypercholesterolemic diseases, total cholesterol, LDL-cholesterol, coronary heart disease (heart attacks and strokes), inflammation, deep-vein thrombosis immunoregulatory diseases, cardiovascular diseases, and/or neurodegenerative disorders in humans and animals. The method comprises administering policosanol and HMG-Co-A reductase inhibitor which together effectively lower serum cholesterol levels. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to HMG-Co-A reductase inhibitor.

A composition comprises one or more long chain alcohols (policosanols) and/or their respective acids (policosanoic acids) and one or more ascorbic acid derivatives, including all biologically acceptable salts or solvates or prodrugs of at least one such derivative or of the salts or of the solvates thereof and is used for the treatment and prevention of a variety of conditions and disorders.

A composition is provided which contains policosanol and niacin and/or niacin derivatives and which may be used for treating and or reducing hypercholesterolemic diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, Lp(a), triglycerides, coronary heart disease (heart attacks and strokes), inflammation, immunoregulatory diseases, cardiovascular diseases, deep vein thrombosis, anxiety, depression and/or neurodegenerative disorders, and/or raise HDL cholesterol in humans and animals. The method comprises administering policosanol and niacin and/or niacin derivatives which together effectively lower the LDL/HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to niacin and/or niacin derivatives.

A composition is provided which contains policosanol and omega-3 fatty acids and which may be used for treating and or reducing hypercholesterolemic diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, triglycerides, coronary heart disease (heart attacks and strokes), sudden cardiac death, ventricular fibrillation, tachycardia, hypertension, inflammation, thrombosis, deep-vein thrombosis, stroke, macular degeneration, autoimmune and/or immunoregulatory diseases, cardiovascular diseases, anxiety, depression and/or neurodegenerative disorders, and/or raise HDL cholesterol in humans and animals. The method comprises administering policosanol and omega-3 fatty acids which together effectively lower the LDL/HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to omega-3 fatty acids.

Statin therapy has revolutionized the treatment of cardiovascular disease, but not all patients can take the appropriate level of statins because of their side effects. The present invention provides compositions that provide potent cholesterol lowering while minimizing the damaging side effects to liver, muscles, and neurons, and has the added benefit of reducing chronic systemic inflammation, which is an independent determinant of cardiovascular disease and all-cause mortality. The current invention presents pharmaceutical compositions for reducing cholesterol and chronic systemic inflammation comprising therapeutically effective amounts of: at least one lipid-lowering agent chosen from HMG-CoA reductase inhibitors, high-dose controlled-release niacin, red yeast rice, or policosanol; and at least one antiinflammatory natural product chosen from alpha-lipoic acid and corosolic acid. To those in need of such treatment, the current invention also provides safe methods for reducing high serum cholesterol or chronic inflammation, or for simultaneously reducing both cholesterol and chronic inflammation via treatment with therapeutically effective daily doses of pharmaceutical compositions as described herein. The present invention provides mammals with compositions and methods for concurrently reducing cholesterol and inflammation as a prevention or treatment for many age-related diseases and disorders.

A composition is provided which contains policosanol and chromium and/or chromium salts and which may be used for treating, preventing and or reducing metabolic syndrome, hypercholesterolemia and hypoglycemia related diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, triglycerides, coronary heart disease (heart attacks and strokes), inflammation, deep-vein thrombosis, immunoregulatory diseases, cardiovascular diseases, obesity, insulin resistance, dyslipidemia, raised blood pressure, fatigue, premenstrual syndrome, anxiety, depression and/or neurodegenerative disorders, and/or raising HDL cholesterol and/or lean body mass in humans and animals. The method comprises administering policosanol and chromium and/or chromium salts which together effectively lower blood glucose levels and lower the LDL/HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to chromium and/or chromium salts.

The present invention provides pharmaceutical compositions, methods, combinations, and kits for treating a disorder related to elevated serum cholesterol concentration, for example, hypercholesterolemia, atherosclerosis, elevated LDL plasma levels, low HDL plasma levels, hypertriglyceridemia, hyperlipidemia, hypertension, cholesterol gallstones, and lipid storage diseases. The compositions, methods, combinations, and kits of the present invention are pharmaceutical compositions comprising atherapeutically effective amount of a lipid regulating agent, such as a HMG-CoA reductase inhibitor, and compound that inhibits cholesterol synthesis at a point between the formation of acetate and mevalonate. A typical pharmaceutical composition of the invention contains and effective amount of atorvastatin and an effective amount of policosanol.

The present invention provides methods for the treatment and/or amelioration of inflammation in a subject, including humans, by administering to a subject a therapeutically effective amount of a biologically active mixture of high purity, high molecular weight straight chain primary aliphatic alcohols (referred to collectively herein as policosanol). Also included are methods of reducing levels of C-reactive protein in a subject, comprising administering to a subject a therapeutically effective amount of policosanol.

Improved delivery systems and delivery methods for supporting and promoting healthy sexual function, for preventing sexual dysfunction, or for treatment of sexual dysfunction. A compositions including one or more cGMP-specific PDE5 inhibitors and/or dopaminergic agonists is administered in the form of a breath-care strip, mint or lozenge, or a food or beverage product. The cGMP-specific PDE5 inhibitor comprises an ingredient selected from the group consisting of sophoflavescenol, vardenafil, tadalafil, and sildenafil. The dopaminergic agonist comprises apomorphine. Vitex agnus-castus extract, and one or more of lipoic acid, L-Arginine, folic acid, trimethylglycine, policosanol, carnitine, biotin, and acetyl L-Carnitine may also be included in the delivery vehicle.

A composition containing EPA and EHA, preferably derived from fish oil, in combination with at least one of oleuropein, allicin, and policosanol having anti-inflammatory, anti-thrombotic, immunomodulatory activity as well as activity to lower triglycerides and low density lipoprotein, to increase high density lipoprotein, and to lower both systolic and diastolic blood pressure.

A composition is provided which contains policosanol and B vitamins and which may be used for treating and or reducing hypercholesterolemia and hyperhomocysteinemia diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, Lp(a), triglycerides, homocysteine, coronary heart disease (heart attacks and strokes), carotid artery disease, inflammation, deep-vein thrombosis, immunoregulatory diseases, cardiovascular diseases, anxiety, depression, neurodegenerative disorders (such as but not limited to Alzheimers), and/or raise HDL cholesterol in humans and animals. The method comprises administering policosanol and B vitamins which together effectively lower the risk of heart disease. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to B vitamins.

The present invention provides methods for treating or preventing the development of macular degeneration-related disorders in a subject, including humans by administering to a subject therapeutically effective amount of a biologically active mixture of high purity, high molecular weight straight chain primary aliphatic alcohols (referred to collectively herein as policosanol).

A composition is provided which contains policosanol and biotin and which may be used for treating, preventing and or reducing metabolic syndrome, hypercholesterolemia and hypoglycemia related diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, triglycerides, coronary heart disease (heart attacks and strokes), inflammation, deep-vein thrombosis, immunoregulatory diseases, cardiovascular diseases, obesity, insulin resistance, dyslipidemia, raised blood pressure, fatigue, premenstrual syndrome, anxiety, depression and/or neurodegenerative disorders, and/or raising HDL cholesterol in humans and animals. The method comprises administering policosanol and biotin which together effectively lower blood glucose levels and lower the LDL/HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to biotin.

The invention provides a novel composition and method for reducing “bad” cholesterol and increasing “good” cholesterol. The composition of the invention comprises a food product having sugar cane juice. The sugar can juice preferably contains policosanols. A method of preventing or treating cardiovascular disease comprising administering a composition comprising sugar cane juice is also provided.

A composition for increasing the bioavailability of nutrients in humans and animals comprising an oil base emulsion into which nutrients selected from the group comprising omega fatty acids, vitamin D, Co Q10, green tea extract, and policosanol are added.

A composition and method for lowering total cholesterol levels and triglyceride levels and for reducing homocysteine levels in a human has policosanol, which is a mixture of fatty alcohols derived from sugar cane wax, omega fatty acids which are DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid) and vitamins B6 (pyridoxine hydrochloride), B12 (cobalamin) and folic acid.

Compositions, novel isolation sources and processes, and uses for unique policosanol containing compositions are disclosed. Seed and vegetable processing byproduct and/or “waste” streams are disclosed as containing policosanols with various relative amounts of the various long chain fatty/waxy alcohols. The policosanols are isolated and may be combined with other phytochemical/processing products, and are used in numerous food, beverage, health and/or nutraceutical applications.

The invention discloses an orally disintegrating tablet containing policosanol. The tablet is composed of the following raw materials by weight: 1.5- 4.5 parts of policosanol, 15.0-30.0 parts of a lipid material, 30.0-60.0 parts of a freeze-drying protective agent and 0.1-0.5 part of a flavoring agent. Meanwhile, the invention also discloses a preparation method of the orally disintegrating tablet. The orally disintegrating tablet prepared according to the invention can be conveniently applied to elderly patients with dysphagia and poor compliance, at the same time, the drug is released quickly, so that the bioavailability of the drug is improved. The drug exists in the preparation in a liposome form, so that the drug solubility can be increased, the drug storage life is prolonged, and theeffect of covering bad taste of the drug is also achieved.

A pharmaceutical composition and method for modifying levels of cholesterol is described. Implementations of a pharmaceutical composition may comprise milk thistle and one of niacin, policosanol, and both niacin and policosanol. Implementations of a pharmaceutical composition may be administered using a method for reducing total cholesterol, LDL cholesterol, and triglycerides and increasing HDL cholesterol levels in a human or animal. The method may include the step of administering a pharmaceutically effective amount of a pharmaceutical composition that includes milk thistle and one of niacin, policosanol, and both niacin and policosanol to a human or animal.

The present invention provides nanoparticulate policosanol, and octacosanol formulations including these particles, as a well as methods of using the particles and formulations for treatment and prophylaxis of various diseases and conditions.

The invention relates to the technical field of policosanol preparations, and provides a policosanol-containing solid dispersion, the policosanol-containing solid dispersion comprises policosanol, a surfactant and a carrier, and the surfactant is a nonionic surfactant used for auxiliary dispersion; the particle size of the solid dispersion is not greater than 5 microns. The invention provides a controlled-release tablet containing policosanol and a preparation method of the controlled-release tablet. The tablet comprises a double-layer tablet core and a controlled-release film layer wrapping the double-layer tablet core; the double-layer tablet core is composed of a drug-containing layer and a boosting layer; the drug-containing layer comprises policosanol, a surfactant, a filler, a carrier, an adhesive and a lubricant; the content of policosanol in each controlled-release tablet is more than or equal to 5mg. The particle size of policosanol in the drug can be greatly reduced, the dispersity and solubility of policosanol can be improved, the release rate of policosanol can be controlled, the release time and the medicine taking interval can be prolonged, and then the bioavailability of policosanol in a human body and the medicine taking compliance of policosanol can be improved.